Skip to main content
. 2018 Aug 30;9:964. doi: 10.3389/fphar.2018.00964

Table 2.

Overall completion rates for each HRQL measure at end of core phase (week 18) across treatment arms.

HRQL measure Total % (n/N) LE (n/N) HE (n/N) Placebo (n/N)
QOLCE 84% (N = 166/197) 54/65 58/69 54/63
QOLIE-AD-48 36% (N = 37/102) 13/31 14/38 10/33
QOLIE-31-P 49% (N = 33/67) 10/21 11/23 12/23

HE, high exposure; LE, low exposure.